Visi / NASDAQ / Capricor Therapeutics

Capricor Therapeutics

Capricor Therapeutics

Investuok be komisinių

Pirk ir parduok dalines akcijas vos už 1 €

Informacija ir statistika

Dienos intervalas
1 D.−100,00 %
3 MĖN.−100,00 %
1 SAV.−100,00 %
6 MĖN.−100,00 %
1 MĖN.−100,00 %
1 M.−100,00 %
SIMBOLIS
CAPR
RINKA
NASDAQ
ISIN
US14070B3096

Data

Uždara

Pokytis

Pokytis (%)

Atvira

Didelė

Maža

7,59−0,57−7,51 %8,168,347,37
7,53−0,50−6,64 %8,039,107,38
8,03−0,75−9,34 %8,789,497,99
8,41−0,30−3,57 %8,718,988,23
8,30−0,91−10,96 %9,219,358,19
9,53−0,68−7,14 %10,2110,219,25
10,24−0,71−6,93 %10,9510,959,87
11,221,3712,21 %9,8511,239,01
8,87−0,78−8,79 %9,6510,068,85
9,850,717,21 %9,1410,008,55
9,000,293,22 %8,719,118,30
8,60−0,04−0,47 %8,648,698,15
8,920,738,18 %8,198,947,90
8,241,0112,26 %7,238,327,15
7,240,364,97 %6,887,456,67
6,38−0,20−3,13 %6,586,646,14
6,630,395,88 %6,246,936,24
6,230,233,69 %6,006,405,90
6,100,355,74 %5,756,315,67
5,74−0,17−2,96 %5,915,955,68
5,93−0,10−1,69 %6,036,085,80
6,130,335,38 %5,806,355,80
5,88−0,72−12,24 %6,606,755,79
6,610,081,21 %6,536,836,47
6,65−0,16−2,41 %6,816,926,54
6,71−0,50−7,45 %7,217,256,68
7,270,638,67 %6,647,336,64
6,59−0,17−2,58 %6,766,886,47
6,88−0,38−5,52 %7,267,396,87
7,47−0,32−4,28 %7,797,807,45
7,83−0,22−2,81 %8,058,057,69
8,010,121,5 %7,898,177,80
8,100,516,3 %7,598,257,46
7,750,030,39 %7,727,897,47
7,78−1,01−12,98 %8,798,797,37
8,95−0,09−1,01 %9,049,248,77
8,94−0,38−4,25 %9,329,398,84
9,47−0,56−5,91 %10,0310,709,40
8,57−0,14−1,63 %8,718,968,51
8,710,424,82 %8,298,838,15
8,36−0,25−2,99 %8,618,678,30
8,57−0,03−0,35 %8,608,868,27
8,67−0,59−6,81 %9,269,328,53
9,340,293,1 %9,059,488,89
8,90−0,21−2,36 %9,119,278,84
9,06−0,21−2,32 %9,279,358,96
9,420,495,2 %8,939,798,84
8,56−0,01−0,12 %8,579,078,41
8,56−0,27−3,15 %8,838,908,37
8,81−0,38−4,31 %9,199,248,71
8,370,050,6 %8,328,678,26
8,30−0,26−3,13 %8,568,708,18
8,64−0,42−4,86 %9,069,268,61
9,06−0,09−0,99 %9,159,488,81
9,400,000 %9,409,809,26
9,28−0,55−5,93 %9,839,939,14
9,89−0,17−1,72 %10,0610,659,60
10,01−0,76−7,59 %10,7710,999,85
9,910,505,05 %9,4110,249,07
9,59−0,14−1,46 %9,7310,199,47
10,060,888,75 %9,1810,618,90
9,361,1312,07 %8,239,888,05
8,291,0212,3 %7,278,597,27
6,80−1,21−17,79 %8,018,016,34
6,29−0,51−8,11 %6,807,086,01
6,83−0,83−12,15 %7,667,806,83
7,980,8110,15 %7,177,997,15
7,08−0,42−5,93 %7,508,286,76
7,450,577,65 %6,887,596,59
6,65−1,03−15,49 %7,688,146,05
4,21−0,01−0,24 %4,224,424,14
4,190,266,21 %3,934,303,90
3,930,082,04 %3,853,993,73
3,85−0,18−4,68 %4,034,103,80
4,09−0,07−1,71 %4,164,704,05
4,180,307,18 %3,884,213,88
3,93−0,24−6,11 %4,174,313,84
4,170,040,96 %4,134,424,09
4,200,4310,24 %3,774,203,66
3,85−0,20−5,19 %4,054,663,80
4,191,1226,73 %3,074,212,96
6,57−0,21−3,2 %6,787,215,70
6,991,1716,74 %5,827,835,82
19,70−0,01−0,05 %19,7120,1718,30
19,831,316,61 %18,5220,5418,50
18,91−0,81−4,28 %19,7219,9218,76
19,790,291,47 %19,5020,1618,97
19,50−0,18−0,92 %19,6820,1719,00
19,440,673,45 %18,7719,7918,65
19,12−1,27−6,64 %20,3920,4919,00
20,35−0,28−1,38 %20,6320,7619,60
20,680,090,44 %20,5921,0420,27
20,61−0,66−3,2 %21,2721,3820,17
21,51−1,07−4,97 %22,5822,5821,19
22,500,070,31 %22,4322,5221,76
22,25−0,01−0,04 %22,2623,0321,41
22,22−0,32−1,44 %22,5422,7021,82
22,43−1,14−5,08 %23,5723,8521,64
23,21−0,04−0,17 %23,2524,5622,54
23,07−0,98−4,25 %24,0524,2523,04
24,080,220,91 %23,8624,9923,86
23,80−3,21−13,49 %27,0127,0323,49
26,44−0,57−2,16 %27,0127,4025,66
30,401,003,29 %29,4030,9329,29
29,51−0,37−1,25 %29,8829,9929,19
29,600,872,94 %28,7329,9928,53
29,34−0,16−0,55 %29,5030,1928,89
28,380,100,35 %28,2829,2227,65
27,950,672,4 %27,2828,7026,97
26,05−0,79−3,03 %26,8427,0325,60
26,720,682,54 %26,0426,9626,00
25,800,682,64 %25,1226,1225,02
25,04−0,32−1,28 %25,3625,6424,65
25,33−0,67−2,65 %26,0026,4225,01
26,01−0,54−2,08 %26,5526,9725,07
26,16−0,99−3,78 %27,1527,3826,00
26,71−1,17−4,38 %27,8827,9526,56
27,950,180,64 %27,7728,4627,51
27,640,612,21 %27,0327,8626,92
27,34−0,71−2,6 %28,0528,2627,09
28,53−0,99−3,47 %29,5229,5228,03
29,96−0,03−0,1 %29,9930,5029,54
29,11−0,10−0,34 %29,2129,3628,77
29,14−0,28−0,96 %29,4229,8728,89
29,36−0,07−0,24 %29,4329,4528,85
28,87−0,71−2,46 %29,5829,9328,66
29,580,822,77 %28,7629,9228,17
29,011,495,14 %27,5229,1227,08
26,92−1,08−4,01 %28,0028,0026,60
28,01−0,98−3,5 %28,9929,1927,38
28,79−0,32−1,11 %29,1129,8328,53
29,81−0,69−2,31 %30,5030,9229,37
30,33−0,17−0,56 %30,5031,9429,26
31,52−0,06−0,19 %31,5832,0530,92
31,901,605,02 %30,3032,5530,02
30,380,882,9 %29,5031,2728,50
33,94−0,01−0,03 %33,9534,2633,02
34,381,243,61 %33,1434,5032,88
32,96−0,74−2,25 %33,7034,3431,58
33,502,296,84 %31,2133,6431,06
30,91−2,59−8,38 %33,5033,5930,85
33,580,521,55 %33,0634,6432,74
32,46−1,44−4,44 %33,9034,1132,31
33,98−1,02−3 %35,0035,8533,62
35,10−0,20−0,57 %35,3035,4534,13
35,271,403,97 %33,8735,3433,06
33,86−1,14−3,37 %35,0035,0732,86
35,00−0,61−1,74 %35,6135,9934,53
35,340,982,77 %34,3635,4733,76
34,21−0,46−1,34 %34,6736,8233,90
34,70−0,66−1,9 %35,3635,6634,35
34,59−0,70−2,02 %35,2935,3733,44
35,040,220,63 %34,8235,3034,07
34,720,712,04 %34,0134,7733,38
34,543,339,64 %31,2135,9930,90
31,20−0,34−1,09 %31,5431,6829,58
31,610,391,23 %31,2232,1330,98
31,60−1,27−4,02 %32,8733,0031,29
31,970,601,88 %31,3731,9830,33
31,68−0,30−0,95 %31,9833,1431,40
32,113,029,41 %29,0932,3928,91
30,12−0,33−1,1 %30,4531,7429,95
30,401,886,18 %28,5230,4728,29
27,77−1,15−4,14 %28,9229,2727,50
28,90−0,72−2,49 %29,6230,4528,37
29,950,511,7 %29,4430,2429,09
29,900,722,41 %29,1830,4429,04
28,87−0,73−2,53 %29,6029,9128,39
30,100,431,43 %29,6730,3228,15
29,10−2,12−7,29 %31,2232,4529,10
31,170,732,34 %30,4431,2529,40
30,90−0,35−1,13 %31,2531,5030,41
31,190,541,73 %30,6531,8430,14
30,560,040,13 %30,5232,4430,19
30,50−2,50−8,2 %33,0033,0029,40
33,42−0,52−1,56 %33,9434,2132,25
33,571,073,19 %32,5035,0832,50
33,400,902,69 %32,5036,4932,08
30,63−0,18−0,59 %30,8131,4028,99
27,902,498,92 %25,4128,8825,07
25,820,321,24 %25,5025,8625,10
25,50−0,94−3,69 %26,4426,5825,34
25,840,210,81 %25,6326,5225,12
26,860,170,63 %26,6927,5526,30
27,930,200,72 %27,7327,9827,13
27,89−0,51−1,83 %28,4028,4527,45
28,350,361,27 %27,9928,8527,90
27,910,260,93 %27,6528,0327,06
27,87−0,28−1 %28,1529,0827,36
28,51−0,19−0,67 %28,7029,4027,54
29,153,6812,62 %25,4729,2325,07
25,532,549,95 %22,9926,1522,80
23,030,542,34 %22,4923,3422,05
22,45−1,79−7,97 %24,2424,3622,27
23,67−0,33−1,39 %24,0024,4823,23
24,20−0,57−2,36 %24,7725,0823,81
24,63−0,44−1,79 %25,0725,4524,49
25,190,471,87 %24,7225,3124,30
24,721,365,5 %23,3625,2123,23
23,03−1,66−7,21 %24,6924,8022,71
24,50−0,28−1,14 %24,7824,7923,70
24,881,837,36 %23,0524,9222,81
23,091,325,72 %21,7723,0921,75
21,89−0,81−3,7 %22,7023,0021,83
22,611,014,47 %21,6022,7021,06
21,57−2,29−10,62 %23,8623,8621,43
23,52−0,17−0,72 %23,6923,7223,10
23,620,612,58 %23,0123,6822,80
23,20−0,82−3,53 %24,0224,1423,01
24,17−0,17−0,7 %24,3424,7424,08
24,310,451,85 %23,8624,6023,52
24,20−0,91−3,76 %25,1125,7023,58
24,350,190,78 %24,1624,8823,96
24,04−0,64−2,66 %24,6824,6823,53
24,790,281,13 %24,5125,0024,23
24,790,522,1 %24,2725,4424,12
24,511,044,24 %23,4724,8623,24
23,84−2,36−9,9 %26,2026,2023,15
25,55−0,31−1,21 %25,8626,2225,07
26,310,230,87 %26,0826,9325,70
26,131,405,36 %24,7326,4424,66
24,81−3,13−12,62 %27,9428,4924,35
28,31−0,67−2,37 %28,9829,3627,52
28,860,100,35 %28,7629,2428,01
28,96−1,04−3,59 %30,0030,0928,21
30,040,411,36 %29,6330,7129,59
29,690,160,54 %29,5329,9029,20
29,680,792,66 %28,8930,1228,51
28,90−0,18−0,62 %29,0829,7428,59
29,501,575,32 %27,9329,9827,78
27,811,605,75 %26,2129,4426,11
26,190,080,31 %26,1126,9926,04
26,150,311,19 %25,8426,8525,60
26,02−0,03−0,12 %26,0526,7125,78
26,550,652,45 %25,9027,1725,87
26,02−0,53−2,04 %26,5527,0725,59
27,18−0,81−2,98 %27,9928,4727,15
28,670,682,37 %27,9929,2327,51
27,38−0,62−2,26 %28,0028,3427,02
28,561,946,79 %26,6231,4426,24
26,890,170,63 %26,7228,6226,01
25,40−2,99−11,77 %28,3930,5823,05
29,96−0,04−0,13 %30,0040,3721,50
6,36−0,39−6,13 %6,756,786,15
6,651,3019,55 %5,357,155,35
5,350,091,68 %5,265,925,22
5,190,5410,4 %4,655,204,63
4,600,153,26 %4,454,844,30
4,64−0,94−20,26 %5,585,614,40
5,750,122,09 %5,636,005,51
5,69−0,13−2,28 %5,826,015,67
5,770,091,56 %5,685,895,60
5,640,081,42 %5,565,775,54
5,690,091,58 %5,605,995,53
5,600,000 %5,605,825,53
5,77−0,06−1,04 %5,836,035,71
5,87−0,31−5,28 %6,186,545,85
6,200,304,84 %5,906,395,66
5,56−0,44−7,91 %6,006,275,43
5,93−0,35−5,9 %6,286,335,90
6,280,000 %6,286,416,15
6,220,162,57 %6,066,266,03
6,060,010,17 %6,056,416,01
6,07−0,38−6,26 %6,456,466,06
6,510,162,46 %6,356,546,17
6,21−0,55−8,86 %6,766,836,19
6,920,7410,69 %6,187,086,12
6,180,000 %6,186,316,12
6,18−0,02−0,32 %6,206,416,17
6,200,040,65 %6,166,336,05
6,13−0,06−0,98 %6,196,286,11
6,23−0,12−1,93 %6,356,376,10
6,37−0,05−0,78 %6,426,496,32
6,400,071,09 %6,336,566,29
6,250,101,6 %6,156,546,01
6,16−0,59−9,58 %6,756,826,13
6,69−0,03−0,45 %6,726,886,62
6,700,081,19 %6,626,806,46
6,72−0,41−6,1 %7,137,156,70
7,09−0,53−7,48 %7,627,627,06
7,620,111,44 %7,517,817,48
7,48−0,05−0,67 %7,537,707,45
7,50−0,30−4 %7,807,807,44
7,810,536,79 %7,287,877,24
7,36−0,57−7,74 %7,937,937,24
7,97−0,03−0,38 %8,008,067,64
7,820,617,8 %7,217,887,21
7,21−0,20−2,77 %7,417,637,11
7,410,202,7 %7,217,637,16
7,090,689,59 %6,417,276,35
6,52−0,29−4,45 %6,817,326,43
6,190,030,48 %6,166,286,05
6,150,091,46 %6,066,316,06
6,09−0,51−8,37 %6,606,606,08
6,650,223,31 %6,436,666,29
6,400,172,66 %6,236,496,16
6,08−0,13−2,14 %6,216,276,04
6,220,010,16 %6,216,386,11
6,04−0,39−6,46 %6,436,575,98
6,36−0,11−1,73 %6,476,476,27
6,440,335,12 %6,116,526,04
6,33−0,21−3,32 %6,546,616,31
6,480,101,54 %6,386,526,14
6,35−0,28−4,41 %6,636,766,33
6,740,7410,98 %6,006,765,81
5,94−0,38−6,4 %6,326,325,68
6,28−0,03−0,48 %6,316,436,23
6,330,071,11 %6,266,406,19
6,280,000 %6,286,366,18
6,26−0,05−0,8 %6,316,436,17
6,25−0,08−1,28 %6,336,546,20
6,47−0,08−1,24 %6,556,606,30
6,60−0,50−7,58 %7,107,106,50
7,100,081,13 %7,027,296,93
7,01−0,10−1,43 %7,117,236,94
7,17−0,48−6,69 %7,657,676,90
7,67−0,09−1,17 %7,767,997,60
7,70−0,15−1,95 %7,857,997,68
7,960,293,64 %7,677,987,59
7,78−0,45−5,78 %8,238,307,75
8,300,232,77 %8,078,607,92
8,040,222,74 %7,828,087,60
7,81−0,37−4,74 %8,188,337,77
9,071,1612,79 %7,919,437,91
8,070,263,22 %7,818,077,54
7,740,070,9 %7,677,827,52
7,670,000 %7,677,797,35
7,68−0,13−1,69 %7,817,907,20
7,90−0,03−0,38 %7,938,287,72
8,180,182,2 %8,008,557,77
8,180,354,28 %7,838,487,51
6,74−0,29−4,3 %7,037,106,61
6,79−0,23−3,39 %7,027,286,72
7,060,456,37 %6,617,086,43
6,48−0,32−4,94 %6,806,806,29
6,820,192,79 %6,637,076,48
6,520,243,68 %6,286,786,24
6,27−0,63−10,05 %6,906,966,19
6,88−0,28−4,07 %7,167,276,88
7,16−0,09−1,26 %7,257,456,97
7,240,070,97 %7,177,436,83
7,17−0,20−2,79 %7,377,466,95
7,38−0,06−0,81 %7,447,496,85
7,640,658,51 %6,998,636,75
11,40−0,02−0,18 %11,4211,5310,62
11,420,968,41 %10,4611,8710,34
10,170,191,87 %9,9810,299,87
9,900,000 %9,9010,109,65
10,250,111,07 %10,1410,5610,11
10,020,353,49 %9,6710,109,45
9,700,010,1 %9,6910,029,48
9,93−1,22−12,29 %11,1511,199,88
11,150,908,07 %10,2511,5710,00
10,18−0,15−1,47 %10,3310,509,80
10,050,818,06 %9,2410,478,91
9,251,3514,59 %7,909,357,83
7,68−0,32−4,17 %8,008,026,93
8,26−3,13−37,89 %11,3911,466,07
11,94−0,09−0,75 %12,0312,6211,86
12,190,171,39 %12,0213,5011,58
12,380,272,18 %12,1112,4211,75
11,78−1,89−16,04 %13,6713,8011,76
13,940,966,89 %12,9813,9712,67
13,14−1,04−7,91 %14,1814,2612,30
13,890,594,25 %13,3014,2113,05

Susijusios diskusijos

MarkyBoy212

prieš 5 dienas

Big Week, good luck everyone

I am still very on the fence on this since the Adcom. I hope we all make money when the decision arrives

MarkyBoy212

praėjusią savaitę

A new buy rating and 2 maintained buys very nice

A new buy rating and 2 maintained buys very nice, hoping this gets approval after earnings and award

ByronKS

praėjusią savaitę

Capricor earnings report

See the Capricor Therapeutics earnings report below. Good luck! 🤞🏼🍀 https://web.quartr.com/link/companies/5913/events/732825/report?rp=0&documentId=4012432

MarkyBoy212

prieš 2 savaites

Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology

Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology

TerraNova23

prieš 2 savaites

Anyone else think this will fail?

According to Adam Feuerstein, Capricor faces two major risks: Weak Clinical Evidence: The FDA may consider Deramiocel's efficacy data insufficient for approval. Public Pressure on the FDA: Capricor's public statements could suggest concerns about its chances of approval. And there is still the 3-9 vote from before.

MarkyBoy212

prieš 2 mėnesius

Will be good to have data out

Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress

Prayers

prieš 3 mėnesius

This too (and yh I DO wish I did this in CFD lol)

This too (and yh I DO wish I did this in CFD lol)

GGGGM

prieš 3 mėnesius

Thank God for this stock today

$CAPR to the rescue, thank you thus far... NFA

kosen

prieš 3 mėnesius

This pattern looks exactly like yesterday.

If it completely duplicates yesterday’s pattern, we see 11.5 Today???

kosen

prieš 3 mėnesius

What do we think

At a loss now, watching a bit

GGGGM

prieš 3 mėnesius

We going up.. The News is here.. NFA.

$CAPR would soar today as the long awaited news is finally here. The FDA accepted a major amendment to Capricor's Biologics License Application (BLA) containing 24-month Phase 3 HOPE-3 extension data. Instead of issuing an immediate rejection, the FDA extended the PDUFA target action date to November 22, 2026. I got in early at $8 and waiting to see above 11 and above.. Note that THIS IS NOT A FINANCIAL ADVICE... NFA

SKM2086

prieš 3 mėnesius

PT - $54

I'm going with a conservative $25-30. We're on the right track now. Definitely close to making permanent moves upwards. https://uk.investing.com/news/stock-market-news/oppenheimer-upgrades-capricor-stock-rating-on-regulatory-update-93CH-4846076

MarkyBoy212

prieš 3 mėnesius

Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA

Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA nice news guys

Hazlaw1234

prieš 3 mėnesius

$CAPR feels like one to watch very closely today 👀

The official PDUFA target date is tomorrow, Saturday 22 August, but with that falling on a weekend there’s a very real possibility we hear something from the FDA today instead. As of now there’s been no decision announced, so I’d expect a lot of eyes on CAPR once the US session gets going and especially into after hours. Could be a very important day for the stock. Definitely worth keeping notifications on. NFA

Walsemaj

prieš 3 mėnesius

Lots of red today across the market

This is going back up

Lookafterthepennies

prieš 3 mėnesius

Lawsuit

What’s with the rise in news of a lawsuit

Šiame puslapyje gali būti bendruomenės sukurto turinio, už kurį „Trading 212“ neatsako. Visada atlik savo tyrimą. „Trading 212“ teikia tik vykdymo paslaugą, bet neteikia investavimo konsultacijų ar portfelio valdymo paslaugų.

Investavimas be komisinių visiems

Pirk ir parduok Capricor Therapeutics Inc +0,06 $ (0,8 %) ir daugiau nei 13 000 pasaulinių vertybinių popierių ir ETF

Gali būti taikomi kiti mokesčiai. Žr. mūsų sąlygas ir mokesčius.

Peržiūrėk mūsų sąlygas ir mokesčius čia

phone

Įsigyk vertybinių popierių iškart

Pasirink mėgstamiausią įmonę

Pasirink, kiek investuoti

Gauk akcijų per kelias sekundes

Turto kaupimas – įprotis.
Automatizuokite jį naudodami Pies.

Investuok į paruoštus arba susikurk savo investicijų rinkinius, pasirinkdamas iš daugybės vertybinių popierių ir ETF

Sužinok daugiau

Sužinok daugiau

Žiūrėti vaizdo įrašą

Turėk net brangiausių akcijų, tokių kaip „Google“, „Amazon“ ir „Apple“

Žiūrėti vaizdo įrašą

Peržiūrėk visas prekybos priemones

Pagalba visą parą

29 sekundžių vidutinis atsako laikas

Pradėk kaupti turtą jau dabar

Prisijunk prie daugiau nei 5 mln. naudotojų

Atsisiųsti programėlę

Atidaryti sąskaitą

Atsisiųsk mobiliąją programėlę

qr-code

Visi pateikti statistiniai duomenys yra globalūs. Klientų skaičius atspindi finansuotas sąskaitas.

Puiku

Įvertinta 4,6/5, remiantis 108 764 atsiliepimais apie

Trustpilot

Įvertinta 4,6/5, remiantis 108 764 atsiliepimais apie

Trustpilot

Pakviestas

Great app very easy to use and lots of…

Great app very easy to use and lots of information. Always upto date with balances and share prices etc.

Pakviestas

Smooth experience

The whole thing is smooth and seamless and makes things easy overall.

Pakviestas

Really easy to use

Really easy to use. Secure and has the best functionality and features.

Pakviestas

Easy to keep up with as informed…

Easy to keep up with as informed everyday or week on interest made . Easy to set up account . No problems .

Pakviestas

Easy to operate and work with

Easy to operate and work with. Works very fast and accurately.

Pakviestas

How you rate the app

This app is so easy to use and safe really love it.

Pakviestas

I opened a cash ISA with them

I opened a cash ISA with them. It was really straightforward to do and interest is added daily. Nice ,easy to use app as well.

Pakviestas

Easy to navigate makes investing…

Easy to navigate makes investing interesting, transferred my investments from HL which was very straightforward and now not paying dealing fee’s Very Happy

Pakviestas

App is easy to work

App is easy to work Good interest rate Daily interest updates

Pakviestas

Very good and informative always stay…

Very good and informative always stay on track with your investments

Pakviestas

Reliable

Reliable, trustworthy app to store your money and to build on your existing wealth if you are financially sensible and smart.

Pakviestas

Great app

Great app. I would recommend to anyone that’s into investing and making their money grow .

Pakviestas

Very easy app to register and use

Very easy app to register and use! Really pleased.

Pakviestas

Clear app

Clear app. Easy to invest. Took a whike for money to get in because i did it from bank rather than in app

Pakviestas

Very smooth and user friendly

Very smooth and user friendly. Have had zero issues having moved from other brokerages. Will keep using.

Pakviestas

Easy to set up and to regular monitor…

Easy to set up and to regular monitor how its performing.

Pakviestas

Competitive rates and quick transfers

Very good on money transfers in and out. They take place immediately unlike some other providers. Very competitive rate on Cash ISA

Pakviestas

Customer support is quick and…

Customer support is quick and effective. The app is well organised and easy to use. Would reccommend for anyone even complete beginners.

Pakviestas

Easy to set up the Cash ISA

Easy to set up the Cash ISA, funds arrived in account almost immediately. Great to see interest accrual amounts daily.

Pakviestas

Reliable

Reliable, Secure. Using it for past 3 years

Pateikiami keli teigiami mūsų klientų atsiliepimai

Mūsų apdovanojimai

Dažniausiai užduodami klausimai

Kokia yra Capricor Therapeutics akcijos kaina?

Dabartinė Capricor Therapeutics kaina yra 7,59 $.

Koks yra Capricor Therapeutics52 savaičių maksimumas?

52 savaičių maksimumas Capricor Therapeutics yra 40,37 $.

Koks yra Capricor Therapeutics 52 savaičių žemiausias lygis?

52 savaičių žemiausias Capricor Therapeutics kursas yra 2,96 $.

Koks yra Capricor Therapeutics savaitės rezultatas?

Per pastarąją savaitę Capricor Therapeutics kaina pasikeitė −20,36 %.

Koks yra Capricor Therapeutics mėnesio našumas?

Per pastarąjį mėnesį Capricor Therapeutics kaina pasikeitė 14,14 %.

Koks yra Capricor Therapeutics 3 mėnesių rezultatas?

Per pastaruosius tris mėnesius Capricor Therapeutics kaina pasikeitė −4,89 %.

Koks yra Capricor Therapeutics 6 mėnesių rezultatas?

Per pastaruosius šešis mėnesius Capricor Therapeutics kaina pasikeitė −71,81 %.

Koks yra Capricor Therapeuticsmetinis našumas?

Per pastaruosius metus Capricor Therapeutics kaina pasikeitė 31,54 %.